Intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy for motor impairment of neuralgic amyotrophy: clinical observations in 10 cases.

BACKGROUND Neuralgic amyotrophy (NA) is a distinct peripheral nervous system disorder characterized by attacks of acute neuropathic pain and rapid multifocal weakness and atrophy unilaterally in the upper limb. The current hypothesis is that the episodes are caused by an immune-mediated response to the brachial plexus, however, therapeutic strategies for NA have not been well established. METHODS AND RESULTS We retrospectively reviewed 15 case series of NA; 10 of the 15 patients received intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy (MPPT) and 9 of these 0 patients showed clinical improvement of motor impairment. CONCLUSION Our clinical observations do not contradict the possibility that IVIg with MPPT may be one of the potential therapeutics for NA, however the efficacy remains to be established. Further confirmatory trials are needed in patients with various clinical severities and phases of NA. Further basic research and confirmatory trials should be performed to survey the efficacy of such immunomodulation therapy for NA.

[1]  S. Kusunoki,et al.  Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy , 2011, Journal of Neuroimmunology.

[2]  N. Alfen.  Clinical and pathophysiological concepts of neuralgic amyotrophy , 2011, Nature Reviews Neurology.

[3]  H. Mefford,et al.  Non-recurrent SEPT9 duplications cause hereditary neuralgic amyotrophy , 2009, Journal of Medical Genetics.

[4]  N. van Alfen,et al.  Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). , 2009, The Cochrane database of systematic reviews.

[5]  S. Pillen,et al.  Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  N. van Alfen,et al.  Long-term pain, fatigue, and impairment in neuralgic amyotrophy. , 2009, Archives of physical medicine and rehabilitation.

[7]  Waseem Fathallah,et al.  Recovery of tacrolimus‐associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient – Case report and review of the literature , 2008, Pediatric transplantation.

[8]  S. Fujioka,et al.  Partial but Rapid Recovery from Paralysis after Immunomodulation during Early Stage of Neuralgic Amyotrophy , 2006, European Neurology.

[9]  B. Engelen,et al.  The clinical spectrum of neuralgic amyotrophy in 246 cases , 2006 .

[10]  N. van Alfen,et al.  The clinical spectrum of neuralgic amyotrophy in 246 cases. , 2006, Brain : a journal of neurology.

[11]  R. Avery,et al.  Neuralgic amyotrophy precipitated by Epstein–Barr virus , 2004, Neurology.

[12]  A. Cruz-Martínez,et al.  Neuralgic amyotrophy: variable expression in 40 patients , 2002 .

[13]  V. Timmerman,et al.  Diagnostic guidelines for hereditary neuralgic amyotrophy or heredofamilial neuritis with brachial plexus predilection , 2000, Neuromuscular Disorders.

[14]  Josemir W Sander,et al.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. , 2000, Brain : a journal of neurology.

[15]  P. Nijweide,et al.  Function of osteocytes in bone , 1994, Journal of cellular biochemistry.

[16]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[17]  I. Kanazawa,et al.  N‐acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain‐Barré syndrome , 1994, Annals of neurology.

[18]  C. Koski,et al.  Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy. , 1993, Archives of neurology.

[19]  S. Barbieri,et al.  High‐dose intravenous immunoglobulin therapy in multifocal motor neuropathy , 1993, Neurology.

[20]  J. Lott,et al.  Estimation of reference intervals for total protein in cerebrospinal fluid. , 1989, Clinical chemistry.

[21]  E. Streib,et al.  Neuralgic amyotrophy: an increasingly diverse entity. , 1988, Muscle & nerve.

[22]  E. Beghi,et al.  Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970–1981 , 1985, Annals of neurology.

[23]  R. Dejong,et al.  Paralytic brachial neuritis. Discussion of clinical features with review of 23 cases. , 1960, JAMA.